Introduction
JC virus (JCV), a member of the family of polyomavirus, was discovered in 1971 in the brain tissue of a patient with progressive multifocal leukoencephalopathy (PML). 1 The virus persistently infects kidney cells. 2, 3 In addition, the virus has also been found to be associated with some CNS tumors, such as oligoastrocytoma, oligodendroglioma, and medullablastomas. 4 The virus has also been detected in the upper and lower gastrointestinal tract and other non-neural tumors, such as colon cancers, [5] [6] [7] [8] esophageal cancers, 9 gastric cancers, 10 and lung cancer.
11
JCV has a naked icosahedral capsid and contains small, circular double-stranded DNA. The genome size of the virus is about 5100 kbp. 12 The circular genome of JCV contains two regions, the early and late transcription units. The early region encodes the large tumor and small tumor antigens. The late region encodes the structure capsid proteins VP1, VP2, and VP3, and a small regulatory protein, agnoprotein. Earlier, JCV VP1 has been cloned and expressed in the baculovirus, 13, 14 Escherichia coli, 15 and yeast. 16 The recombinant VP1 protein is able to self-assemble to form a virus-like particle (VLP). The characteristics of the VLP, such as its typical morphology, its binding to cells, internalization, and its transportation to nucleus are similar to native JCV virions 13 indicating that the JCV VLP has the potential to deliver foreign genes into susceptible cells for expression.
Using polyomavirus as a gene delivery vector, Osterman et al. 17 first described the idea of applying murine polyomavirus capsid as a gene delivery vector for therapeutic purposes in 1970. Since then, progress has been made in the use of polyomavirus capsid as a gene delivery vector. [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] However, the efficiency of gene transduction using polyomavirus vector is low. In part, this may have been caused by inefficient DNA packaging. For example, when in vitro DNA packaging using osmotic shock was carried out, 18 ,21 DNA molecules were diffused into the virus particles by increasing the permeability of the VLP; however, only partial or short DNA fragments could be accommodated and protected within the particle. 28 Another DNA packaging method based on capsomere reassembly has been shown to have low efficiency in terms of gene transduction because capsomere aggregation occurs during the process of assembly. 29, 30 These limitations on the use of polyomavirus vectors because of problems with packaging DNA molecules need to be addressed.
In this study, the efficiency of DNA packaging using the JCV VLP was improved and this resulted in a higher efficiency of gene transduction. As shown in this study, the growth of human colon cancer cells was greatly inhibited after the thymidine kinase (tk) gene product in the form of a DNA molecule was delivered by JCV VLPs in a nude mouse model.
Results

DNA packaging into the JCV VLPs
To package the expression plasmids of green fluorescent protein (gfp) and tk into the JCV VLPs, the E. coli bearing VP1 and either the gfp or tk plasmid was cultured in LB medium containing ampicillin and kanamycin. After induction of VP1 expression, the VP1 self-assembled to form VLPs. The procedures for VLP purification have been earlier described. 31, 32 The CsCl gradient purified gfp-VLP was examined by electro-microscopy. The purified particles at 1.32 g cm -3 density were found to be comprised of virion-like particles (Figure 1a) , and the population at 1.29 g cm -3 density contained empty capsids-like particles (Figure 1b) . To examine the encapsidated DNA, the virion-like particles were disrupted and polymerase chain reaction was used to detect pEGFP-N3, which was amplified as an 846 bp fragment ( Figure 2a) . Next, the plasmid was extracted from the virion-like particles and transformed to E. coli selecting for kanamycin-resistant colonies on LB plates ( Figure 2b) ; the presence of these transformants indicated that the whole pEGFP-N3 plasmid could be packaged in the virion-like particles, although the plasmid DNA was not detectable after extraction from the VLPs. The plasmid from these kanamycin-resistant colonies was extracted by the alkaline lysis method and digested with the restriction enzyme Pvu II. The fragments after digestion (4121 and 608 bp) were characteristic of pEGFP-N3 and confirmed that the whole plasmid had been encapsidated (Figure 2c ). Taken together, these results indicated that the complete pEGFP-N3 was packaged into the VLPs as the VP1 self-assembled in E. coli. In the same way, pUMVC1-tk was also packaged into the VLPs by the same method and then used for the gene delivery experiments.
Gene transduction by gfp-VLP in cell culture
The reporter plasmid pEGFP-N3 was packaged in the JCV VLPs and this was designated as gfp-VLP. To investigate gene delivery by the VLP, human colon carcinoma cells, COLO-320 HSR, were infected with purified gfp-VLP. Lipofectamine was used to transfect pEGFP-N3 plasmid as a positive control; pEGFP-N3 plasmid alone was incubated with the cells as a negative control. After 72 h culture, gene transduction was examined with a confocal microscope. The results showed that the pEGFP-N3 plasmid alone was unable to transduce the COLO-320 HSR cells and no green fluorescence protein was detected in these cells ( Figure 3a) . As a positive control, lipofectamine was able to transduce pEGFP-N3 into the COLO-320 HSR cells and gfp expression was detected (Figure 3b ). Interestingly, the gfp-VLP was able to successfully transduce the gfp gene into COLO-320 HSR cells to give a positive gfp expression in cells of approximately 90% (Figure 3c ). The results indicate that the JCV VLP was able to package and deliver pEGFP-N3 into human colon adenocarcinoma and that this resulted in gene expression.
In vivo gene transduction of gfp-VLP in a nude mouse bearing COLO-320 HSR tumor nodule
The VLP was also able to package and delivery gfp plasmid into human colon adenocarcinoma cells in cell culture. Gene delivery by the gfp-VLP in a nude mouse model was further performed. To determine the gene transduction of the VLP in vivo, nude mice bearing a human COLO-320 HSR tumor were generated by subcutaneously inoculating COLO-320 HSR cells into the nude mice. At day 7 post-inoculation, gfp-VLP was intravenously (IV) injected into the mouse through tail Figure 1 Electromicrographs of JCV gfp-VLP. CsCl density gradient purified gfp-VLP was examined by electron microscopy. The purified particles at 1.32 g cm -3 (a) and 1.29 g cm -3 (b) densities.
Gene delivery using the JC virus-like particle L-S Chen et al vein for every other day for a total of six injections. The tumor nodules and the mouse organs, including brain, heart, lung, liver, kidney, and spleen, were removed for gene transduction examination. Slices of organs were observed under a confocal microscope. The results revealed that the green fluorescence protein was expressed only in the tumor nodule and not in any other organ (Figure 4 ). Specifically, green fluorescence Gene delivery using the JC virus-like particle L-S Chen et al protein was not detected when pEGFP-N3 DNA was injected as a control ( Figure 4a ). None of the organs, including brain, heart, lung, liver, spleen, and kidney of the COLO-320 HSR bearing nude mice, showed gfp expression even when injected with gfp-VLP ( Figure 4b ). However, the COLO-320 HSR tumor nodule showed strong green fluorescence protein expression after IV injection with gfp-VLP ( Figure 4b ). The findings show that pEGFP-N3 was specifically delivered into the human colon cancer cells in the mice when VLPs were introduced by IV injection.
Cytotoxicity assay of tk-VLP
After showing that JCV VLPs are able to package pEGFP-N3 and deliver the plasmid into human colon cancer cells in vitro and in vivo, pUMVC1-tk, for suicide gene expression, was also packaged into the VLP by the same method. By polymerase chain reaction, it was confirmed that pUMVC-1 tk was also packaged in the JCV VLP (data not shown). To determine the cytotoxicity effect of tk-VLP in the tumor cells, MTT testing was carried out. On day 2-5 after infection, MTT tests were performed to determine cell viability and the results were compared with the parallel controls. The negative control groups of the cytotoxicity assay, JCV VLP infection with ganciclovir (GCV) treatment, PBS addition with or without GCV treatment, tk-VLP infection without GCV treatment, did not show any cytotoxic activity ( Figure 5 ). The positive control group, pUMVC1-tk plasmid transfection with GCV treatment showed a cytotoxicity effect ( Figure 5 ). However, the cytotoxicity effect was only found after tk-VLP infection with GCV treatment ( Figure 5 ). At day 5, the cell viability had been reduced to about 32% compared with the negative control groups ( Figure 5 ). The cytotoxicity assay shows that the VLP was able to deliver the tk gene into human colon cancer cells for expression and subsequently this gene was able to cause cell death after treatment with GCV.
Anti-tumor effect of tk-VLP in mice
After showing in vitro gene delivery, the anti-tumor effect of tk-VLP in a mouse model was further investigated. COLO-320-HSR cells were subcutaneously inoculated into the dorsum of nude mice. At day 7 post-inoculation, tk-VLP or PBS was IV injected into the mice every other day for a total of six injections. Three days after first injection of the tk-VLP or PBS, GCV was intraperitoneally injected and treatment lasted for 3 weeks as described in Materials and methods. The results showed that tumor growth was totally inhibited and that only a scar remained on the dorsum of the injection site in the group treated with tk-VLP followed by GCV (Figure 6a ). The growth of the tumor cells was not inhibited in the negative control groups, including tk-VLP without GCV treatment and PBS with or without GCV treatment ( Figure 6 ). The average tumor volume of the tk-VLP injection with GCV treatment was 20.28 ± 12 mm 3 , which is much smaller than that of the control groups. The average tumor volume of the control groups was 8536.88±234 mm 3 ( Figure 6 ). These results show that the IV injected tk-VLP seemed to specifically target the susceptible human colon adenocarcinoma cells and inhibit the growth of the tumor cells in the nude mice. Gene delivery using the JC virus-like particle L-S Chen et al
Discussion
This study shows that the JCV VP1 was able to selfassemble to form a virus-like structure when expressed in E. coli. In addition, the VLP was able to encapsidate plasmid DNA in E. coli to form a virion-like structure.
The virion-like particles and empty capsid-like particles could be separated and purified by CsCl density gradient. The VLP was able to deliver the encapsidated gfp and tk plasmid DNA into human colon cancer cells for expression. When combined with GCV treatment, the tk-VLP was able to cause cytotoxicity in infected human colon cancer cells. Furthermore, tail vein-injected tk-VLP was able to target human colon cancer cells in nude mice and cell growth was subsequently inhibited after treatment with GCV. Thus, VLPs are an efficient means of being about gene transduction. The major capsid protein, VP1, of JCV is able to selfassemble to form VLP when expressed in insect, 13, 14 yeast, 16 and E. coli 15 without the presence of the other minor capsid proteins, VP2 and VP3. In this study, we found that VLP was able to package DNA in E. coli. It is still not clear how the plasmid DNA molecules are encapsidated in the VLP. It has been shown that VP1 is able to bind DNA without sequence specificity. 31, 32 The DNA-binding domain is located at the N-terminus, which contains a positively charged stretch of amino acids. It is possible that DNA molecules interact with VP1 and are encapsidated when the VP1 self-assembles in E. coli. The encapsidated plasmid DNA seems to be well packaged and highly protected. If gfp-VLPs are treated with Dnase, the level of transduction remains the same as when gfp-VLPs that have not been so treated (data not shown). This supports the idea that the plasmid DNA is well protected in the VLP after E. coli packaging. This contrasts with the plasmid DNA packaged by osmotic shock, which is not well protected. 15, 28 The VLP is able to accommodate and protect DNA molecules up to 2 kbp by the in vitro package method. 28 Furthermore, the efficiency of gene transduction was about 1-2% when the osmotic shock VLPs were used. 21 This is very much lower than the efficiency of gene transduction in the present system in which the efficiency was about 80% when VLPs were produced by in vivo DNA packaging. This finding indicates that the efficiency of DNA packaging by the VLP may strongly affect the efficiency of gene transduction when using the polyomavirus VLP. In addition to the high efficiency of DNA packaging in E. coli by the VLP, various DNA constructs containing Cell survival (%) Figure 5 In vitro cytotoxicity analysis of tk-VLP. Cell viability after various treatments was examined, including JCV VLP with GCV treatment (-~-), PBS control with GCV (-'-) or without GCV treatment (-}-), tk-VLP with GCV (-m-), or without GCV treatment (-n-), the pUMVC1-tk plasmid with CVG treatment (-n-) and pUMVC1-tk transfected by the lipofectamine with the GCV treatment (-K-). Gene delivery using the JC virus-like particle L-S Chen et al gene of interest should be easily encapsidated into the particles without viral genetic materials. This may be an advantage if this approach is used for human gene therapy. Factors for determination of JCV host range are still not clear. However, serotonin receptor and a-(2,6)-linked sialic acid serve as receptor and co-receptor for JCV infection. 37 Internalization of the virus is clathrin dependent. 38 After entry, the virus co-localizes with transferrin to the endosomes. The virus may then be transported from the cytosol to the nucleus through the actin cytoskeleton. 39 In addition to this cytoskeleton transport of the virus, a putative nuclear localization signal (MAPTKRKGERKD) in the N-terminal region of VP1 may mediate nuclear translocation through nuclear pore. 36 The virus would seem then to uncoat, which exposes the encapsidated DNA to the nucleus allowing gene expression. The intracellular trafficking pathway of polyomavirus is different from that of retrovirus vectors. Retrovirus vectors infect dividing cells, which allow access of the gene of interest to the nucleus for expression. 37 Importantly, polyomavirus vector is able to deliver DNA into non-dividing cells for gene expression.
On the basis of the similar characteristics of the JCV VLP and the virion, it is possible to use the VLP as a gene or drug delivery vector that is able to alter the cell functioning of JCV susceptible cells and inhibit JCV replication in JCV-infected cells. Human colon cells are susceptible to JCV infection. 5, 8 The JCV VLP was able to deliver a suicide gene into human colon cancer cells for expression and subsequently this was able to cause cell death in the presence of GCV as shown in this study. Up to the presence, no effective drug that is able to inhibit JCV replication has been developed. The use of siRNAs targeted against JCV large tumor and agnoprotein have been shown to be effective at inhibiting JCV replication. [38] [39] [40] Therefore, it may be possible to deliver siRNA expression plasmids by the JCV VLP into the JCVinfected cells, such as oligodendrocytes, and thus inhibit JCV replication because JCV VLP and the virus seem to share the same cell surface receptor.
Human oligodendrocytes, 1 B cells, 41 and kidney epithelial cells 3 are permissive to JCV infection. In addition, the JCV DNA has been found in many human tissues including the gastrointestinal track, 10 lung, 11 colon, [5] [6] [7] [8] and esophagus. 9 This indicates that many human tissues maybe susceptible to JCV VLP infection. In this study, human colon cancer cells were subcutaneously injected into nude mice to produce tumors, then JCV VLPs were injected into the mice through the tail vein. The VLP targeted the cancer cells and transduced genes into these cells allowing expression. The results indicate that the VLPs may travel by circulation and are able to specifically target susceptible cells at various locations in a mouse. This is important for the possible treatment of metastatic cancer cells. Although the organs of the gfp-VLP-treated mouse, including brain, heart, lung, liver, spleen, and kidney, did not show evidence of gene transduction by the VLP, which may be because mouse cells are not susceptible to JCV infection. In this context, VLPs may be able to target some susceptible normal human tissues as well as colon cancer cells. Therefore, the tissue-specific targeting of the VLP in human body needs to be of concern in any clinical trial.
However, interactions of the cellular receptor with the viral attachment domain of the viral vector may determine the host range and restrict the virus' tissue tropism. JCV VP1 contains three external loops, BC, DE, and HI loops. 42 These loops on the surface of the capsid particle may be responsible for the cellular interactions. Recently, it has been shown that Arg-56 and Gly-57 on the BC loop of JCV VP1 interact with cellular a-(2,6)-linked sialic acid during initial specific attachment at the early phase of infection. 33 Therefore, it may be possible to genetically alter the viral attachment domain on the surface of the JCV VLP and change the specific targeting using ligand-receptor design.
Materials and methods
Cell lines
The human colon adenocarcinoma (COLO-320 HSR) cell line was purchased from the American Type Culture Collection (CCL 220.1, Manassas, VA, USA). Cells were maintained in RPMI-1640 medium supplemented with 10% fetal calf serum and antibiotics.
Packaging of the exogenous plasmid DNA by the JCV VLP
The JCV VP1 expression plasmid, D pFLAG-VP1, was sequenced and constructed as described earlier. [31] [32] [33] . The plasmids, pEGFP-N3 (Clontech, Palo Alto, CA, USA), for gfp expression, or pUMVC1-tk (Aldevron, Fargo, ND, USA), for tk expression, were then transformed into the JCV VP1 expressing E. coli, JM109. The transformed E. coli strains, each bearing two plasmids, either D pFLAG-VP1 and pEGFP-N3 or D pFLAG-VP1 and pUMVC1-tk, were grown in LB medium with ampicillin and kanamycin to select for D pFLAG-VP1 and pEGFP-N3 or pUMVC1-tk, respectively. VP1 protein expression was induced during early exponential phase by the addition of 0.5 mM (final concentration) isopropyl b-D-1-thiogalactopyranoside for 8 h at 30 1C. Assembly of the JCV VLP in E. coli was then able to simultaneously package the second plasmid that was present in the E. coli, namely pEGFP-N3 or pUMVC1-tk. The procedure for VLP purification has been earlier described. 31, 32 Briefly, the supernatant of the E. coli lysate was collected and subjected to 20% sucrose cushion centrifugation and CsCl velocity gradient centrifugation. Fractions with hemagglutination activity were collected and dialyzed against Tris-buffered saline (10 mm Tris-HCl, pH 7.4, 150 mm NaCl). The VLPs were concentrated using a Centricon filter (Millipore, Billerica, MA, USA). The packaged pEGFP-N3 and pUMVCl-tk in their individual VLPs were then designated as gfp-VLP or tk-VLP, respectively.
Electron microscopy of the VLP
CsCl gradient purified gfp-VLP and tk-VLP were mounted on carbon formvar-coated grids and stained with 2% uranyl acetate. Specimens were examined using a Joel 2000-CX electron microscope (Joel, Tokyo, Japan) at 120 kV.
Nucleic acid extraction from VLPs
To analyze the nucleic acids that had been encapsidated in the VLPs, 30 mg of CsCl gradient purified VLP were ), 1% SDS, and 25 mM EDTA at 37 1C for 30 min. An equal volume of phenol-chloroform was added to extract the nucleic acid that was released. 44 The mixture was then centrifuged at 12 000 g for 5 min. The aqueous phase was mixed with sodium acetate (final concentration 0.3 M) and three volumes of cold absolute ethanol to precipitate the nucleic acid. After incubation at À20 1C for 1 h, the nucleic acid was pelleted by centrifugation at 14 000 g for 15 min at 4 1C. Finally, the pellet was resuspended in 50 ml of distilled water.
Transfection and pseudoinfection
Transfection of the reporter plasmid, pEGFP-N3, was performed using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA) as described by the manufacturer. Human colon carcinoma cells (COLO-320 HSR) were cultured in 35 mm dishes with RPMI-1640 medium supplemented with 10% fetal bovine serum; 1 mg of pEGFP-N3 plasmid was mixed with 1 ml of Lipofectamine 2000 reagent. The mixture was incubated at room temperature for 1 h before transfection. Cells were then transfected with the lipofectamine mixture. For pseudoinfection with the VLP, the human carcinoma cells were cultured in 35 mm dishes overnight with RPMI-1640 medium supplemented with 10% fetal bovine serum. Next day, the cells were centrifuged at 3000 g to pellet down the suspended cells, washed with PBS twice, and then resuspended in 50 ml of PBS; 10 mg of gfp-VLP were used to infect the human colon carcinoma cells for 1 h at 4 1C. After infection, the cells were washed twice with cold PBS to remove the free gfp-VLP. Complete RPMI-1640 was added to the culture and incubated at 37 1C with 5% CO 2 for 72 h. Next, an aliquot of 100 ml of the infected COLO-320 HSR cells were placed in the wells of the cytospine and spin at 1000 g for 3 min. The expression of green fluorescence protein after transfection or pseudoinfection was monitored by a confocal microscope.
Cytotoxicity assays
The cytotoxicity of tk to COLO-320 HSR cells was examined by standard MTT assay. 45 . Cells were pseudoinfected with 1 mg per well of tk-VLP in RPMI-1640 medium supplemented with 10% fetal bovine serum for 1 h in 96-well flat-bottom microtiter plates (BD Biosciences Clontech, San Diego, CA, USA). Each well contained approximately1 Â 10 4 cells. The cells were then incubated with or without GCV (Cymeven), (Roche, Palo Alto, CA, USA) (10 mg ml -1 ) at 37 1C with 5% CO 2 . On days 2, 3, 4, and 5 post-infection, the microtiter plates were centrifuged at 1000 g to pellet down the suspended COLO-320 HSR cells and washed twice with PBS. A total of 100 ml of RPMI-1640 medium, containing 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, a tetrazole) solution (5 mg ml -1 ), (Sigma, St Louis, MO, USA) was added to each well and followed by incubation at 37 1C with 5% CO 2 for 1 h. After incubation, the microtiter plates were centrifuged again and the supernatants were removed; 100 ml of dimethylsulfoxide was added to each well. After 30 min incubation, the absorbance of each well was read by an ELISA plate reader equipped with a 595 nm filter (Biotek Instruments, Winooski, VT, USA).
Tumor targeting of gfp-VLP in a mouse
Five-week-old male nude mice were purchased from the National Laboratory Animal Center, Taipei, Taiwan, and housed and maintained in controlled specific pathogenfree airflow cabinets. Animals were given water and standard chow ad libitum and kept on a 12 h light/dark cycle. All animal procedures were performed according to approved protocols and in compliance with recommendations for proper care and use of laboratory animals of the Institutional Animal Care and Use Committee of National Chung Cheng University. Human colon carcinoma cells (COLO-320 HSR) were subcutaneously inoculated into the nude mice. The total inoculated cell number was 10 6 for each injection. After 1 week, the gfp-VLP or pEGFP-N3 was then IV injected into the tail vein of the COLO-320 HSR tumor bearing mice. Inoculation dosage was determined by titration at the beginning of the study. The injections of 70 mg gfp-VLP were given every other day, six times in total. After completing the IV administration, the mice were anesthetized and various organs, including brain, heart, lung, liver, spleen, kidney, and the tumor nodule, were removed and embedded in optimum cutting temperature compound. Cryosectioning was performed to give slices of 10 mg thickness. The slices were counterstained with 4 0 , 6-diamidino-2-phenylindole. Fluorescent protein expression was detected with a Zeiss LM-510 confocal microscope.
Inhibition of tumor growth by tk-VLP in a mouse
Human COLO-320 HSR cells were harvested from subconfluent cultures, washed once with a serum-free medium, and resuspended in PBS. To induce tumor nodule formation, 1 Â 10 6 COLO-320 HSR cells were injected subcutaneously into the left flanks of mice. Seven days later, the mice were randomized into four groups (four mice each) and subjected to the following different treatments: tk-VLP (70 mg per injection) with or without GCV; PBS with or without GCV. The mice were administered with tk-VLP or PBS every other day through the tail vein. The mice were intraperitoneally injected with GCV (100 mg kg -1 ) daily after the first IV injection of the tk-VLP or PBS. Tumor volume was determined using the equation: (a 2 Â b Â P)/6 as described earlier, 36 in which 'a' is the tumor width and 'b' the tumor length. Measurements were performed twice a week with a caliper. The mice were euthanized and killed when the tumor reached 10 000 mm 3 in volume, when the tumor became ulcerated or at the end of the experimental procedure.
Statistical analysis
Data were expressed as mean ± s.d. Analysis of data was performed using the Student's t-test and one-or two-way ANOVA tests, with a value of Po0.05 being considered to represent a significant difference.
